Skip to main content

Early value dossiers for medical technologies

The essential tool to understand the value proposition for your product and position it well with reimbursement/HTA stakeholders

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Publication Digest: Quality and transparency of evidence for implantable cardiovascular medical devices assessed by the CORE-MD consortium

05 Feb 2024

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. In a recent publication, Siontis et al. conducted a systematic review of the clinical evidence supporting 71 high-risk cardiovascular devices before and after market access in the European Union (CE-marking) between 2000 and 2021. The authors aimed to assess the quantity and quality of published studies, revealing a notable insufficiency in publicly available data and a lack of randomized clinical trial data published before CE-mark approval, with most studies being non-randomized and conducted in small populations without the provision of power calculations. 

Access the full-text article here.